BR112022026275A2 - Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso - Google Patents

Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso

Info

Publication number
BR112022026275A2
BR112022026275A2 BR112022026275A BR112022026275A BR112022026275A2 BR 112022026275 A2 BR112022026275 A2 BR 112022026275A2 BR 112022026275 A BR112022026275 A BR 112022026275A BR 112022026275 A BR112022026275 A BR 112022026275A BR 112022026275 A2 BR112022026275 A2 BR 112022026275A2
Authority
BR
Brazil
Prior art keywords
methods
diones
pyridine
exhibit
mnk
Prior art date
Application number
BR112022026275A
Other languages
English (en)
Inventor
J Price Theodore
J Sahn James
Original Assignee
4E Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4E Therapeutics Inc filed Critical 4E Therapeutics Inc
Publication of BR112022026275A2 publication Critical patent/BR112022026275A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

PIRIDINA-1,5-DIONAS QUE EXIBEM INIBIÇÃO DE MNK E SEUS MÉTODOS DE USO. Trata-se de compostos que têm atividade como inibidores de MNK. Uma modalidade fornece compostos que têm a Estrutura (II): Fórmula (II) ou um sal far-maceuticamente aceitável, estereoisômero, tautômero ou pró-fármaco deste, sendo que R1a, R1b, R2, X, Y e L são conforme definidos na presente invenção. Métodos associados à preparação e ao uso de tais compostos, composições farmacêuticas que compreendem tais compostos e métodos para modular a atividade de MNK também são fornecidos.
BR112022026275A 2020-06-30 2021-06-30 Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso BR112022026275A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046325P 2020-06-30 2020-06-30
PCT/US2021/039982 WO2022006331A2 (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Publications (1)

Publication Number Publication Date
BR112022026275A2 true BR112022026275A2 (pt) 2023-03-14

Family

ID=79315594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026275A BR112022026275A2 (pt) 2020-06-30 2021-06-30 Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso

Country Status (11)

Country Link
US (1) US20230286983A1 (pt)
EP (1) EP4171565A2 (pt)
JP (1) JP2023533616A (pt)
KR (1) KR20230041715A (pt)
CN (1) CN116194112A (pt)
AU (1) AU2021300363A1 (pt)
BR (1) BR112022026275A2 (pt)
CA (1) CA3183551A1 (pt)
IL (1) IL299512A (pt)
MX (1) MX2022016516A (pt)
WO (1) WO2022006331A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023278686A1 (en) * 2021-06-30 2023-01-05 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2547905T3 (es) * 2010-02-26 2015-10-09 Evotec International Gmbh 4-[Cicloalquiloxi(hetero)arilamino]-tieno[2,3-d]pirimidinas que tienen actividad inhibidora de la Mnk1/Mnk2 para composiciones farmacéuticas
EP2747769B1 (en) * 2011-08-22 2017-08-02 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
SG11201803234TA (en) * 2015-10-29 2018-05-30 Effector Therapeutics Inc Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
CA3064000A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
AU2019366947A1 (en) * 2018-10-24 2021-06-03 Effector Therapeutics, Inc. Crystalline forms of Mnk inhibitors
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
CN110256432A (zh) * 2019-06-27 2019-09-20 诺沃斯达药业有限公司 抑制mnk1和mnk2的多环化合物

Also Published As

Publication number Publication date
US20230286983A1 (en) 2023-09-14
CN116194112A (zh) 2023-05-30
WO2022006331A2 (en) 2022-01-06
EP4171565A2 (en) 2023-05-03
WO2022006331A3 (en) 2022-02-10
JP2023533616A (ja) 2023-08-03
AU2021300363A1 (en) 2023-02-09
WO2022006331A9 (en) 2022-03-03
CA3183551A1 (en) 2022-01-06
WO2022006331A8 (en) 2023-03-16
KR20230041715A (ko) 2023-03-24
MX2022016516A (es) 2023-03-28
IL299512A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
BR112023018785A2 (pt) Composto cíclico fundido com pirimidina, método de preparação do mesmo e uso do mesmo
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
BRPI1011838B8 (pt) compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk
BR112022003514A2 (pt) Degradadores bifuncionais de brd9 e seus métodos de uso
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
BR112018010107A8 (pt) Composição farmacêutica para o tratamento ou prevenção de nash
CO2022017622A2 (es) Inhibidores de quinasa nek7
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
AR114082A1 (es) INHIBIDORES DE LA PI4KIIIb
CO2022019131A2 (es) Inhibidores de la quinasa nek7
BR112022026275A2 (pt) Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones